KOSDAQBiotech & Pharma493280

IMBiologics

₩12,380▲ 1.48%2026-11-18 close
Market Cap
₩183.8B
Turnover
₩600M
Volume
50K
Shares out.
14.9M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating losses return as licensing income fades

After licensing income from 2024 faded, disclosed results showed a net profit attributable to controlling shareholders in 2025, but operating losses returned in the second and third quarters of 2026, and the next checkpoints are IMB-101 Phase 2 data and any further licensing deals.

  1. 1

    Disclosed 2025 revenue was KRW 11.6 billion, down 57.9% from the prior year, and operating profit fell 97.9% to KRW 298 million. Net profit attributable to controlling shareholders turned positive at KRW 877 million.

  2. 2

    First-quarter 2026 operating profit of KRW 2.73 billion included milestone income, but operating losses of KRW 2.68 billion in the second quarter and KRW 3.43 billion in the third quarter followed, marking two consecutive loss-making quarters.

  3. 3

    In its March 2026 prospectus, the company projected an operating loss of KRW 5.5 billion for 2026, an operating loss of KRW 27.4 billion for 2027, and operating profit of KRW 67.3 billion for 2028.

  4. 4

    In its May 2026 first-quarter release, the company said cash and equivalents stood at about KRW 127 billion, reflecting the IPO proceeds.

  5. 5

    Its lead asset IMB-101 is slated for re-licensing or M&A discussions based on clinical data expected in the second half of 2027.

02

Business structure

IMBiologics is an antibody drug developer founded in August 2020, focusing mainly on autoimmune diseases and immuno-oncology. Its lead pipeline asset is IMB-101, a bispecific antibody that simultaneously inhibits TNF-α and OX40L, currently in Phase 2 clinical trials for hidradenitis suppurativa.

The single antibody IMB-102 and the in-house ePENDY platform, a multivalent antibody backbone technology, form the two pillars of the pipeline.

In 2024 the company licensed IMB-101 and IMB-102 as a package to Navigator Medicines in the United States and a Chinese pharmaceutical partner, in a deal reported at about KRW 1.8 trillion in total contract value.

However, the cumulative revenue the company has secured from these licensing agreements is USD 33.39 million (about KRW 50 billion), so the total contract value and the revenue actually recognized differ substantially.

Revenue comes mainly from upfront licensing fees and milestone payments rather than product sales, so the timing of revenue recognition depends on clinical progress and commercialization milestones.

In the first quarter of 2026, a USD 5 million milestone tied to first-patient dosing in IMB-101's global Phase 2 trial was reflected in results.

In antibody-drug conjugates (ADCs), the company signed a joint research agreement in August 2025 with China-based biotech GeneQuantum covering linker and payload work on ePENDY, and IMB-201 and IMB-402 are cited as follow-on candidates.

Its customers are global pharmaceutical companies and biotechs, and unlike Samsung Biologics, which centers on contract manufacturing (CDMO), IMBiologics has chosen to build its own pipeline and out-license it.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩7.2B₩2.7B37.8%
2026Q2₩0-₩2.7B—
2026Q3₩0-₩3.4B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩27.6B₩14B-₩11.9B50.7%—−146.8%
2025₩11.6B₩300M₩900M2.6%1.2%2.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 27.6 billion in 2024 to KRW 11.6 billion in 2025, a decline of 57.9% from the prior year. Operating profit dropped from KRW 14 billion in 2024 to KRW 298 million in 2025, down 97.9%, and the operating margin fell from 50.7% to 2.6%.

Press coverage attributed the sharp decline to the base effect after the large 2024 licensing deal.

Net profit attributable to controlling shareholders turned from a loss of KRW 11.9 billion in 2024 to a profit of KRW 877 million in 2025, and net profit including non-controlling interests moved in the same direction, from a net loss of KRW 11.9 billion to a net profit of KRW 877 million.

Operating cash flow fell from KRW 16.9 billion in 2024 to KRW 393 million in 2025, so the recovery in accounting profit did not translate into cash generation of similar size.

At the end of 2025, total liabilities were KRW 1.81 billion and total equity was KRW 73.5 billion, of which the equity attributable to controlling shareholders was also KRW 73.5 billion. The debt ratio (total liabilities divided by total equity) moved from -146.8% in 2024 to 2.5% in 2025.

On a quarterly basis, the first quarter of 2026 showed revenue of KRW 7.23 billion, operating profit of KRW 2.73 billion, and net profit attributable to controlling shareholders of KRW 3.83 billion.

In the second quarter of 2026 the company posted an operating loss of KRW 2.68 billion, a swing into loss from the prior quarter, with a net loss attributable to controlling shareholders of KRW 2.12 billion.

In the third quarter of 2026 the operating loss widened to KRW 3.43 billion and the net loss attributable to controlling shareholders to KRW 3.33 billion. Across the four quarters of 2025, net profit attributable to controlling shareholders totaled KRW 877 million.

The first-quarter profit reflected milestone income, which shows that quarterly results move sharply depending on when licensing and milestone revenue is recognized.

05

Industry analysis

In the autoimmune antibody market, the OX40L class already has competitors in development. Sanofi secured an OX40L and TNF bispecific pipeline, brivekimig, through an acquisition reported at about KRW 5 trillion, and is developing the OX40L monoclonal antibody amlitelimab for atopic dermatitis.

In March 2026, Japan's Kyowa Kirin discontinued development of an antibody directly targeting the OX40 receptor after a case of Kaposi sarcoma, which raised target-safety concerns across the class.

In response, the company stressed that it blocks the ligand OX40L rather than the receptor, and that it inhibits signaling without eliminating immune cells.

Interest in biotechs that rely on licensing has broadened through the NewCo model, and the acquisition by Pfizer of Metsera, which had secured an obesity drug pipeline from D&D Pharmatech, is cited as a representative case.

Compared with Samsung Biologics, which centers on contract manufacturing, IMBiologics out-licenses clinical-stage assets, so its earnings visibility depends more heavily on pipeline progress.

In the March 2026 offering, the share of institutional allocations under mandatory lock-up was high, and the free float on the first trading day was reported at about 14%.

The strong subscription demand shows market expectations, but the gap between the post-listing share price and reported earnings is viewed as driven by individual clinical results rather than the sector cycle.

06

Outlook

The profit projections the company presented in its March 2026 prospectus were revenue of KRW 19.7 billion and an operating loss of KRW 5.5 billion for 2026.

The same projections show revenue of KRW 700 million and an operating loss of KRW 27.4 billion for 2027, then revenue of KRW 97.7 billion and operating profit of KRW 67.3 billion for 2028, a path that depends on milestone-based licensing income and therefore carries substantial variability.

Against that path, the operating losses reported in the second and third quarters of 2026 make the full-year 2026 operating result relative to the KRW 5.5 billion projection the next item to verify in the annual report.

IMB-101's Phase 2 data in hidradenitis suppurativa are planned for the second half of 2027, and the company intends to pursue re-licensing or M&A with global pharmaceutical companies based on them.

The company has said it aims to pursue additional large deals with global pharma in 2028 and to reach global approval and launch by 2032. IMB-102 has been reported to enter clinical trials in 2027.

Offering proceeds are to be deployed into the preclinical and clinical stages of follow-on ADC pipelines IMB-201 and IMB-402.

At the listing, the company said it planned research and development spending of about KRW 37.4 billion across 2026 and 2027 combined, and cash and equivalents of about KRW 127 billion at the end of the first quarter of 2026 are the funding source.

The CEO has said the intrinsic value of the company will grow substantially by 2028, but this is a company target rather than an externally verified forecast.

07

Valuation

PER
—
PBR
—
ROE
1.2%
EPS
—
BPS
—
Dividend per share
₩0

IMBiologics' valuation sits in a range that is hard to read through earnings-based metrics. Operating profit fell from KRW 14 billion in 2024 to KRW 298 million in 2025, and operating losses have continued since the second quarter of 2026.

Because earnings swing between losses and profits, earnings-based multiples can move sharply depending on when licensing revenue is recognized in a given quarter. On a price-to-book basis, the market capitalization sits at a considerable premium to total equity of KRW 73.5 billion at the end of 2025.

That premium is read as reflecting market expectations for the clinical pipeline and the potential for licensing revenue. Press coverage reported that the share price, which jumped sharply above the offering price on the first trading day, has since remained under pressure.

The dividend yield is effectively zero, so the structure places more weight on securing research and development funding than on shareholder returns. For that reason, describing the valuation through pipeline stage and licensing track record is closer to the facts than comparing earnings multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

IMB-101 clinical progress and milestone potential

IMB-101 is a bispecific antibody that inhibits TNF-α and OX40L simultaneously, and it is in Phase 2 trials for hidradenitis suppurativa. First-patient dosing in the global Phase 2 trial triggered a USD 5 million milestone that was reflected in first-quarter 2026 results.

The company says the clinical data expected in the second half of 2027 would form the basis for re-licensing or M&A discussions.

Financial capacity and R&D funding

Cash and equivalents were about KRW 127 billion at the end of the first quarter of 2026, up from KRW 72.7 billion at the end of 2025. The increase included IPO proceeds of KRW 52 billion and milestone receipts.

The company has planned research and development spending of about KRW 37.4 billion across 2026 and 2027, and this funding is the basis of the bullish case on clinical execution.

Licensing track record and NewCo model interest

The company said its licensing agreements have secured USD 33.39 million (about KRW 50 billion) in revenue. Those agreements are presented as examples of partner contracts converting into actual revenue.

Interest in the NewCo model has grown, as illustrated by the Pfizer acquisition of Metsera, which had secured an obesity pipeline from D&D Pharmatech.

09

Bear factors

Sharp revenue and profit decline, then quarterly losses

Revenue fell 57.9% to KRW 11.6 billion in 2025, and operating profit fell 97.9% to KRW 298 million. The second and third quarters of 2026 both posted operating losses, two consecutive loss-making quarters. The third-quarter operating loss of KRW 3.43 billion was wider than the second-quarter loss of KRW 2.68 billion. Under the company's 2027 projection, revenue would fall further to around KRW 700 million.

Timing-dependent revenue and uncertainty

Because revenue relies on licensing fees and milestones, quarterly profit can swing with clinical progress and the timing of partner deals. The gap between the roughly KRW 1.8 trillion contract value from 2024 and the about KRW 50 billion in cumulative revenue illustrates that uncertainty.

The company's projected operating loss of KRW 27.4 billion for 2027 means that losses could last longer if pipeline progress slips.

Target safety concerns and competition

Kyowa Kirin's March 2026 decision to stop developing an OX40 receptor antibody raised safety questions for the class. Sanofi's acquisition of an OX40L and TNF bispecific at a reported value of about KRW 5 trillion means competition in the same class is intense. If Phase 2 results fall short of expectations, the re-licensing strategy itself could be affected.

10

Risk factors

Clinical development risk

Until Phase 2 results for IMB-101 are available, the value of its licensing is uncertain. Failure or delay in the trial would directly affect the timing of data expected in the second half of 2027 and the target of additional large deals in 2028.

If the effect of blocking OX40L in hidradenitis suppurativa is not sufficiently demonstrated, securing follow-on partners could become difficult.

Revenue volatility and financial risk

Because revenue and profit depend on licensing fees and milestones, quarters without new deals can extend losses. The operating losses in the second and third quarters of 2026 illustrate this structure.

If research and development costs rise, the pace at which the roughly KRW 127 billion in cash is used becomes a key point to monitor.

Free float and share price volatility

Because the share of institutional allocations under long-term lock-up was high at listing, the tradable float was limited. As lock-up releases add shares to the float, supply and demand could shift.

After the sharp first-day surge was followed by weakness, the share price could react sharply to earnings releases and clinical news.

11

What to watch next

  1. Late March 2027

    The annual report for fiscal 2026 will disclose full-year revenue and operating results. The next item to check is whether the full-year operating loss, including fourth-quarter results, lands near the company's KRW 5.5 billion 2026 projection.

  2. Before May 15, 2027

    This is when the first-quarter 2027 quarterly report is due. The point to check is whether operating losses that began in the second quarter of 2026 continue, and how much milestone income contributes to quarterly results.

  3. Second half of 2027

    This is the planned timing for data from the Phase 2 trial of IMB-101 in hidradenitis suppurativa. Whether efficacy is demonstrated will shape the conditions for re-licensing or M&A, making it the central event.

  4. 2028

    This is the target timing the company has set for additional large deals with global pharmaceutical companies. The point to verify alongside is how actual profit compares with the 2028 operating profit projection of KRW 67.3 billion.

12

Overall view

IMBiologics is a biotech whose earnings gap became pronounced after the large licensing income recognized in 2024. On a disclosed basis, 2025 revenue was KRW 11.6 billion and operating profit was KRW 298 million, while net profit attributable to controlling shareholders turned positive at KRW 877 million.

The first quarter of 2026 recorded operating profit of KRW 2.73 billion thanks to a clinical milestone, but operating losses followed in the second and third quarters, marking two consecutive loss-making quarters.

Financially, total equity of KRW 73.5 billion at the end of 2025 and cash and equivalents of about KRW 127 billion at the end of the first quarter of 2026 form the base supporting development.

The projections presented in March 2026 show operating losses of KRW 27.4 billion in 2027 and operating profit of KRW 67.3 billion in 2028, placing the timing of earnings recovery in 2028.

The bullish factors are Phase 2 data and the possibility of further licensing, while the bearish factors are the timing dependence of licensing revenue and the safety debate and competition in the OX40 class.

The next checkpoints are the full-year operating results in the 2026 annual report, the first-quarter 2027 quarterly report, and the IMB-101 Phase 2 data in the second half of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. nextunicorn.kr
  3. imbiologics.com
  4. kind.krx.co.kr
  5. innoforest.co.kr
  6. sedaily.com
  7. imbiologics.com
  8. marketin.edaily.co.kr
  9. wikitree.co.kr
  10. dailymedi.com
  11. mt.co.kr
  12. kr.investing.com
  13. news.nate.com
  14. etoday.co.kr
  15. bloter.net
  16. hankyung.com
  17. m.news.nate.com
  18. newspim.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis